SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending amid a mix of political commentary and discussion around the company's performance. The community is actively debating the stock's valuation, potential catalysts, and the influence of its namesake, Donald Trump. Sentiment appears divided, with some users expressing skepticism and others remaining supportive.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid Group is trending despite mixed Q3 earnings, with revenue increases offset by lowered production guidance and continued losses; the community is debating whether the stock's low valuation presents a buying opportunity or signals further decline, and the stock's heavy short interest also fuels discussions of a potential short squeeze; recent news of a convertible note offering and executive departures add to investor uncertainty.

Bitmine Immersion Technologies, Inc. is a blockchain technology company, which engages in industrial scale digital asset mining, equipment sales, and hosting operations. It operates through the Cryptocurrency Mining Industry segment. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

Bitmine Immersion Technologies Inc

BMNR is trending downwards amid concerns about its correlation with Ethereum and potential dilution. The community is actively discussing the company's strategy, including calls for share buybacks and staking, while some express frustration with the stock's performance relative to ETH. Some traders speculate on a possible short squeeze or future recovery, while others are losing faith in the company's leadership.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Strategy is trending as investors discuss its relationship to Bitcoin's price movements and potential exposure. Community members are debating whether to invest in MSTR as a Bitcoin proxy, with some questioning its strategy and others expressing concerns about potential liquidation levels. The conversation also includes discussion of the broader market context of Bitcoin and possible alternative instruments.

Ondas Holdings, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in Boston, MA.

Ondas Holdings Inc

ONDS is trending as investors digest recent news, including a closed acquisition and a new European contract, while also reacting to share dilution. Community discussion revolves around the company's long-term potential in the drone and counter-UAS space versus short-term volatility and market manipulation. Some investors are optimistic about future growth and government contracts, while others express concerns about dilution and sector headwinds.

Luckin Coffee, Inc. engages in providing food and beverage items, and operates coffee retail stores. It has a pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. The company manages pick-up stores, relax stores, and delivery kitchens. It also offers tea, snacks, and light meals through its mobile application. The company was founded by Zhi Ya Qian, Fei Yang and Jin Yi Guo on June 16, 2017 and is headquartered in Xiamen, China.

Luckin Coffee Inc - ADR

$LKNCY is trending amid speculation of a U.S. relisting, driven by the CEO's recent comments, and anticipation for earnings. Community chatter revolves around revenue growth, margins, and the potential impact of institutional investors like Fidelity. Discussions also include speculation about potential acquisitions and competition within the broader coffee market.

Uniting the six native Japanese dog breeds. Kendu is the keeper of peace, the preserver of life, and the protector of unity. Join the pack!!

Kendu

$KENDU is trending as community members highlight its strong dedication to building and real-world applications, despite market conditions. Active community involvement and the development of a permissionless brand with various products and businesses are key talking points. Discussions also emphasize the growing holder base and the project's potential for long-term success within the crypto space.

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull ($BULL) is trending amidst concerns about potential dilution and recent price declines, with some traders pointing to upcoming earnings as a key catalyst. Community sentiment is mixed, with discussions around support levels, insider buying, and comparisons to other fintech companies like Robinhood ($HOOD). Some investors are expressing frustration and questioning the stock's management, while others remain optimistic about the company's long-term growth potential and international expansion.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros is trending as investors discuss the potential of zaltenibart following a recent deal with Novo Nordisk, with some viewing it as a validation of Omeros' science and a financial milestone to advance other programs. Community members are actively speculating on the timing of FDA approval for narsoplimab and discussing potential price targets, with some eyeing a significant upside if key events align. Some traders are also noting short positions and anticipating a potential short squeeze.

Sigma Lithium Corp. engages in the producing of a lithium property. It focuses its project in Minas Gerais. The firm also plans to build a world-class commercial-scale lithium concentration plant. The company was founded on June 8, 2011 and is headquartered in Sao Paulo, Brazil.

Sigma Lithium Corporation

SGML is trending due to recent earnings and discussions around market confusion leading to a potential accumulation phase, despite mixed sentiment. The community is actively debating its future, with some eyeing a repricing opportunity amidst bullish revenue growth, while others express concerns about descending triangles and potential downturns. Broader lithium sector trends and potential short squeezes may also be influencing the stock's movement.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$CRVS  Quick Take 🚀 
 
Soquelitinib AD data keeps trending stronger. Cohort 3 (200 mg BID, 4 weeks) delivered EASI −64.8%, 50% EASI-75, 25% IGA 0/1, rapid itch relief by Day 8, and clean safety. Importantly, responses kept improving beyond Week 4, supporting longer dosing. 
 
Cohort 4 (8 weeks) fully enrolled — data in January. 
 
Angle Pharma (China) running a 12-week AD study with the same Phase 2 doses, completing early Q1, adding independent validation + reducing clinical risk ahead of Phase 2. 
 
Phase II AD trial starts early Q1 ’26 (200 pts, incl. Dupixent/JAK failures). 
 
Oncology: ASH oral presentation in December highlighting soquelitinib’s activity in T-cell lymphoma, reinforcing the mechanism and broader immunology potential. 
 
⸻ 
 
Bottom Line (Catalysts 🚨) 
 
Q4: 
 • ASH (Dec): T-cell lymphoma data strengthens mechanistic confidence + pipeline expansion 
 • Adds visibility to safety, durability, and immunologic relevance 
 
Q1: 
 • Cohort 4 (8-week) AD data — January 
 • Angle Pharma China 12-week AD readout — early Q1 
 • Phase II AD trial initiation (Q1 ’26) 
 
A stacked Q4–Q1 catalyst window with rising conviction in both the AD and T-cell lymphoma programs.

Biotech gambler

Low Float Runners

radgator1

David Scott

hzhou088

Bradly Dalton

David

Bernd Roessle

Dlhayes

StockTwits Web

Corvus Pharmaceuticals Inc

  Quick Take 🚀 
 
Soquelitinib AD data keeps trending stronger. Cohort 3 (200 mg BID, 4 weeks) delivered EASI −64.8%, 50% EASI-75, 25% IGA 0/1, rapid itch relief by Day 8, and clean safety. Importantly, responses kept improving beyond Week 4, supporting longer dosing. 
 
Cohort 4 (8 weeks) fully enrolled — data in January. 
 
Angle Pharma (China) running a 12-week AD study with the same Phase 2 doses, completing early Q1, adding independent validation + reducing clinical risk ahead of Phase 2. 
 
Phase II AD trial starts early Q1 ’26 (200 pts, incl. Dupixent/JAK failures). 
 
Oncology: ASH oral presentation in December highlighting soquelitinib’s activity in T-cell lymphoma, reinforcing the mechanism and broader immunology potential. 
 
⸻ 
 
Bottom Line (Catalysts 🚨) 
 
Q4: 
 • ASH (Dec): T-cell lymphoma data strengthens mechanistic confidence + pipeline expansion 
 • Adds visibility to safety, durability, and immunologic relevance 
 
Q1: 
 • Cohort 4 (8-week) AD data — January 
 • Angle Pharma China 12-week AD readout — early Q1 
 • Phase II AD trial initiation (Q1 ’26) 
 
A stacked Q4–Q1 catalyst window with rising conviction in both the AD and T-cell lymphoma programs.

Gurujoe

@Gurujoe           CRVS 
                            STRONG! 
                        MOORE to COME!

           CRVS 
                            STRONG! 
                        MOORE to COME!

Rocking Rob

@Gurujoe what gets me here - long time investor but in and out at times - is MGMT not blinded to AD study so comments at last CC about moving to PH2 &amp; inferring being able to raise funds / partner “ easily” tells me something.

StockTwits for iOS

 what gets me here - long time investor but in and out at times - is MGMT not blinded to AD study so comments at last CC about moving to PH2 & inferring being able to raise funds / partner “ easily” tells me something.

flubadub

@flubadub Great questions, not blinded to the study in China, which is a 12-week duration, that they are proposing for the phase 2. The only data they’ve published is 4 weeks, and even off drug, there was a gain in efficacy with placebo. I think the 8 week cohort 4 will gain even further efficacy. The published data already puts them then best in class,

 Great questions, not blinded to the study in China, which is a 12-week duration, that they are proposing for the phase 2. The only data they’ve published is 4 weeks, and even off drug, there was a gain in efficacy with placebo. I think the 8 week cohort 4 will gain even further efficacy. The published data already puts them then best in class,

@flubadub The drug they&#39;re comparing is Regeneron/Sonofi’s Dupixent® (dupilumab), which had $18 billion in sales. CRVS’s lead drug modulates additional inflammatory receptors and is a small molecule.

Bahram redjaee

 The drug they're comparing is Regeneron/Sonofi’s Dupixent® (dupilumab), which had $18 billion in sales. CRVS’s lead drug modulates additional inflammatory receptors and is a small molecule.